5-(4-(5-((dimethylamino)methyl)-1-methyl-1H-pyrazol-3-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide

ID: ALA4757235

Chembl Id: CHEMBL4757235

PubChem CID: 162656336

Max Phase: Preclinical

Molecular Formula: C21H25N9O

Molecular Weight: 419.49

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CNC(=O)c1nn(C)c2ccc(Nc3nccc(-c4cc(CN(C)C)n(C)n4)n3)cc12

Standard InChI:  InChI=1S/C21H25N9O/c1-22-20(31)19-15-10-13(6-7-18(15)30(5)27-19)24-21-23-9-8-16(25-21)17-11-14(12-28(2)3)29(4)26-17/h6-11H,12H2,1-5H3,(H,22,31)(H,23,24,25)

Standard InChI Key:  PQZMFSCYCVLYQR-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4757235

    ---

Associated Targets(Human)

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SU-DHL-2 (105 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 419.49Molecular Weight (Monoisotopic): 419.2182AlogP: 1.93#Rotatable Bonds: 6
Polar Surface Area: 105.79Molecular Species: NEUTRALHBA: 9HBD: 2
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 12.52CX Basic pKa: 7.60CX LogP: 1.78CX LogD: 1.37
Aromatic Rings: 4Heavy Atoms: 31QED Weighted: 0.49Np Likeness Score: -1.54

References

1. Grimster NP,Gingipalli L,Barlaam B,Su Q,Zheng X,Watson D,Wang H,Simpson I,Pike A,Balazs A,Boiko S,Ikeda TP,Impastato AC,Jones NH,Kawatkar S,Kemmitt P,Lamont S,Patel J,Read J,Sarkar U,Sha L,Tomlinson RC,Wang H,Wilson DM,Zehnder TE,Wang L,Wang P,Goldberg FW,Shao W,Fawell S,Dry H,Dowling JE,Edmondson SD.  (2020)  Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.,  30  (19): [PMID:32717371] [10.1016/j.bmcl.2020.127433]

Source